Beam Therapeutics financials
$24.52+1.20%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $490.0K | $31.7M | $114.1M | $9.7M | $8.5M | $7.5M | $30.1M | $14.3M | $11.8M | $7.4M | $316.2M | $17.2M |
| Gross profit | $490.0K | $31.7M | $114.1M | $9.7M | $8.5M | $7.5M | $30.1M | $14.3M | $11.8M | $7.4M | $316.2M | $17.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$126.8M | -$107.2M | -$17.4M | -$126.8M | -$120.2M | -$119.3M | -$100.0M | -$106.5M | -$104.9M | -$104.1M | $132.9M | -$108.3M |
| Net income | -$122.7M | -$94.3M | $244.3M | -$112.7M | -$102.1M | -$108.3M | -$90.4M | -$96.7M | -$91.1M | -$98.7M | $142.8M | -$96.1M |
| Net margin | −25036.3% | −297.2% | 214.1% | −1162.4% | −1206.4% | −1450.2% | −300.5% | −677.5% | −773.5% | −1331.6% | 45.2% | −558.9% |
| Diluted EPS | $-1.18 | $-0.91 | $2.37 | $-1.10 | $-1.00 | $-1.23 | $-1.09 | $-1.17 | $-1.11 | $-1.21 | $1.76 | $-1.22 |
| EBITDA | -$121.3M | -$101.6M | -$11.8M | -$121.3M | -$114.6M | -$113.8M | -$94.6M | -$101.0M | -$99.3M | -$98.7M | $132.9M | -$103.1M |
| Operating cash flow | -$66.1M | -$128.5M | -$83.3M | -$81.5M | -$76.5M | -$103.9M | -$76.4M | -$88.1M | -$83.0M | -$99.7M | $144.8M | -$89.8M |
| Free cash flow | -$68.5M | -$130.7M | -$87.0M | -$86.5M | -$79.6M | -$106.9M | -$79.3M | -$89.7M | -$85.0M | -$102.2M | $141.2M | -$97.7M |
| Diluted shares | 104.3M | 103.3M | 103.1M | 102.6M | 102.0M | 88.0M | 82.8M | 82.4M | 82.3M | 81.7M | 81.0M | 79.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $219.8M | $288.3M | $294.9M | $268.0M | $282.1M | $527.9M |
| Short-term investments | $933.1M | $923.4M | $950.3M | $807.0M | $868.2M | $692.0M |
| Total debt | $100.3M | $100.2M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.39B | $1.48B | $1.48B | $1.31B | $1.39B | $1.47B |
| Total liabilities | $318.9M | $316.4M | $242.8M | $345.1M | $344.3M | $343.8M |
| Shareholders' equity | $1.07B | $1.16B | $1.24B | $966.0M | $1.05B | $1.12B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology